Clinical Trial Update: Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 [Phase 2]

View source ↗

Summary

Phase 2 extension study report on ODM-201 (darolutamide) in castration-resistant prostate cancer, focusing on safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ODM-201 (darolutamide)

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-12-22